Gábor Tomisa

Significance of breath-hold time in dry powder aerosol drug therapy of COPD patients

Alpár Horváth, Imre Balásházy, Gábor Tomisa et al. · European Journal of Pharmaceutical Sciences · 2017 · 55 citations

Asthma, Lung Deposition, Pharmacology +6

Epidemiology of comorbidities and their association with asthma control

Gábor Tomisa, Alpár Horváth, Balázs Sánta et al. · Allergy Asthma and Clinical Immunology · 2021 · 42 citations · Full text

Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort® Turbuhaler® dry powder fixed combination aerosol drug

Árpád Farkas, Ágnes Jókay, Imre Balásházy et al. · European Journal of Pharmaceutical Sciences · 2016 · 34 citations

Aerosol Transport, Allergy, Lung Deposition +8

<p>Prevalence and impact of risk factors for poor asthma outcomes in a large, specialist-managed patient cohort: a real-life study</p>

Gábor Tomisa, Alpár Horváth, Zsuzsanna Szalai et al. · Journal of Asthma and Allergy · 2019 · 32 citations · Full text

Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients

Alpár Horváth, Árpád Farkas, Annamária Szipőcs et al. · European Journal of Pharmaceutical Sciences · 2020 · 25 citations · Full text

Asthma, Pulmonary Care, Inflammatory Lung Disease +20